Literature DB >> 7768593

A toxic shock syndrome toxin 1 mutant that defines a functional site critical for T-cell activation.

C M Cullen1, L R Blanco, P F Bonventre, E Choi.   

Abstract

Toxic shock syndrome toxin 1 (TSST-1), a superantigen produced by Staphylococcus aureus, is a causative agent of toxic shock syndrome (TSS). This superantigen is a potent stimulator of T cells and macrophages/monocytes, resulting in the release of cytokines that are implicated in the pathogenesis of TSS. This study characterizes a mutant TSST-1, derived by site-directed mutagenesis, that has an alanine substitution at histidine 135 (mutant 135). This single-amino-acid change results in a mutant toxin that has lost mitogenic activity for T cells. In contrast to wild-type TSST-1, this mutant does not induce T cells to express interleukin-2, gamma interferon, or tumor necrosis factor beta (TNF-beta). The inability of mutant 135 to activate T cells is not due to a lack of binding to the class II major histocompatibility complex receptor. In addition, the mutant TSST-1 does not induce expression of TNF-alpha, which plays a role in the development of lethal shock. The lack of TNF-alpha induction by mutant 135 is likely due to its inability to activate T cells. These data suggest that the mutation at histidine 135 in TSST-1 affects toxin interactions with the T-cell receptor rather than the class II major histocompatibility complex receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768593      PMCID: PMC173278          DOI: 10.1128/iai.63.6.2141-2146.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Activation of T cells by superantigen in class II-negative mice.

Authors:  A C Avery; J S Markowitz; M J Grusby; L H Glimcher; H Cantor
Journal:  J Immunol       Date:  1994-12-01       Impact factor: 5.422

2.  Expression of the cloned toxic shock syndrome toxin 1 gene (tst) in vivo with a rabbit uterine model.

Authors:  J C de Azavedo; T J Foster; P J Hartigan; J P Arbuthnott; M O'Reilly; B N Kreiswirth; R P Novick
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

3.  A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates.

Authors:  M S Bergdoll; B A Crass; R F Reiser; R N Robbins; J P Davis
Journal:  Lancet       Date:  1981-05-09       Impact factor: 79.321

4.  Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome.

Authors:  P M Schlievert; K N Shands; B B Dan; G P Schmid; R D Nishimura
Journal:  J Infect Dis       Date:  1981-04       Impact factor: 5.226

5.  Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen.

Authors:  T S Jardetzky; J H Brown; J C Gorga; L J Stern; R G Urban; Y I Chi; C Stauffacher; J L Strominger; D C Wiley
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

6.  Induction of human interleukin-1 by a product of Staphylococcus aureus associated with toxic shock syndrome.

Authors:  T Ikejima; C A Dinarello; D M Gill; S M Wolff
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

7.  Toxic-shock-syndrome toxin 1-induced proliferation of lymphocytes: comparison of the mitogenic response of human, murine, and rabbit lymphocytes.

Authors:  N J Poindexter; P M Schlievert
Journal:  J Infect Dis       Date:  1985-01       Impact factor: 5.226

8.  Acquired ability of Staphylococcus aureus to produce toxic shock-associated protein and resulting illness in a rabbit model.

Authors:  J K Rasheed; R J Arko; J C Feeley; F W Chandler; C Thornsberry; R J Gibson; M L Cohen; C D Jeffries; C V Broome
Journal:  Infect Immun       Date:  1985-03       Impact factor: 3.441

9.  Properties and applications of monoclonal antibodies directed against determinants of the Thy-1 locus.

Authors:  A Marshak-Rothstein; P Fink; T Gridley; D H Raulet; M J Bevan; M L Gefter
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

10.  Production of staphylococcal enterotoxin F and pyrogenic exotoxin C by Staphylococcus aureus isolates from toxic shock syndrome-associated sources.

Authors:  P F Bonventre; L Weckbach; J Staneck; P M Schlievert; M Thompson
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

View more
  5 in total

Review 1.  Staphylococcus aureus superantigens and airway disease.

Authors:  Claus Bachert; Philippe Gevaert; Paul van Cauwenberge
Journal:  Curr Allergy Asthma Rep       Date:  2002-05       Impact factor: 4.806

2.  Functional analysis of Mycoplasma arthritidis-derived mitogen interactions with class II molecules.

Authors:  C Bernatchez; R Al-Daccak; P E Mayer; K Mehindate; L Rink; S Mecheri; W Mourad
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

3.  Interleukin-10 (IL-10) Produced by Mutant Toxic Shock Syndrome Toxin 1 Vaccine-Induced Memory T Cells Downregulates IL-17 Production and Abrogates the Protective Effect against Staphylococcus aureus Infection.

Authors:  Kouji Narita; Dong-Liang Hu; Krisana Asano; Akio Nakane
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

4.  Localization of a T-cell epitope of superantigen toxic shock syndrome toxin 1 to residues 125 to 158.

Authors:  W G Hu; X H Zhu; Y Z Wu; Z C Jia
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

Review 5.  Superantigens and nasal polyps.

Authors:  Claus Bachert; Thibaut van Zele; Philippe Gevaert; Lore De Schrijver; Paul Van Cauwenberge
Journal:  Curr Allergy Asthma Rep       Date:  2003-11       Impact factor: 4.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.